There are multiple platforms for developing vaccines against the SARS-CoV-2 virus, including messenger RNA, DNA and molecular clamp. Moderna said last week that it had dosed the first patient in its Phase I mRNA vaccine trial.

LEAVE A REPLY

Please enter your comment!
Please enter your name here